Hamayun Mian, MD
Urology · de Pere, WINPI 1124020870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,062 and has fallen 70.7% since, to $605 in 2025.
Across 272 payments — averaging $22.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$680
- Medtronic$523
- Astellas Pharma US Inc$454
- Teleflex LLC$452
- Dendreon Pharmaceuticals LLC$408
- Procept Biorobotics Corporation$341
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,86594%
- Education$3616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $680 |
| Medtronic(2 entities) | 19 | $523 |
| Astellas Pharma US Inc | 21 | $454 |
| Teleflex LLC | 6 | $452 |
| Dendreon Pharmaceuticals LLC | 14 | $408 |
| Procept Biorobotics Corporation | 5 | $341 |
| Johnson & Johnson | 13 | $330 |
| Sumitomo Pharma America, Inc. | 11 | $306 |
| Pfizer | 15 | $267 |
| Olympus America Inc. | 15 | $245 |
| Endo Pharmaceuticals Inc. | 10 | $241 |
| EDAP Technomed Inc | 10 | $196 |
| Coloplast | 9 | $169 |
| Antares Pharma, Inc. | 13 | $167 |
| Rochester Medical Corporation | 3 | $160 |
| Bayer | 4 | $150 |
| Boston Scientific | 6 | $133 |
| Axonics, Inc. | 6 | $113 |
| Urogen Pharma, Inc. | 5 | $108 |
| Blue Earth Diagnostics | 6 | $101 |
| Angiodynamics, Inc. | 3 | $90 |
| AstraZeneca | 3 | $76 |
| Valencia Technologies Corporation | 1 | $66 |
| Amgen | 3 | $65 |
| Merck | 4 | $63 |
| Urovant Sciences Inc | 3 | $58 |
| Intuitive Surgical | 2 | $56 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $48 |
| Civco Medical Instruments | 1 | $21 |
| Accord Healthcare, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 3 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Halozyme Inc | 1 | $14 |
| Smith+Nephew | 1 | $13 |
| Integra Lifesciences Corporation | 1 | $12 |
| Palette Life Sciences, Inc. | 1 | $12 |
| Foundation Medicine, Inc. | 1 | $12 |
| Myovant Sciences Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$140
- UroLift$128
- UroLift System$126
- ORGOVYX$117
- AquaBeam Robotic System$109
- Nubeqa$109
How this compares
$6,226 in reported general payments places this provider in the 85th percentile of 215 urology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 74 | $957,757 |
| OrgovyxRelugolix | 62 | $163,560 |
| GemtesaVibegron | 51 | $35,036 |
| MyrbetriqMirabegron | 39 | $34,594 |
| Abiraterone Acetate | 26 | $24,737 |
| Tamsulosin Hcl | 159 | $2,594 |
| Trospium Chloride ErTrospium Chloride | 21 | $2,417 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $2,310 |
| Silodosin | 15 | $1,835 |
| Trospium Chloride | 20 | $866 |
| Finasteride | 61 | $829 |
| Oxybutynin Chloride | 22 | $563 |
| Oxybutynin Chloride ErOxybutynin Chloride | 16 | $417 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $415 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 66 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $454 | $992,351113 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $306 | $198,596113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 215 urology providers in Wisconsin.
Other urology in de Pere
- Sean McAdamsde Pere$5K
- Dan GralnekMadison$142K
- Amy GuiseMilwaukee$106K
- Christopher ManakasMadison$87K
- Bahareh Alavi-DunnGreen Bay$62K
- Javier SantiagoMadison$57K
- Kevin FlynnNeenah$56K
- Margaret KnoedlerMadison$31K
- Jeremy ReesePleasant Prairie$27K
- Edwin AbelMadison$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.